Retraction notice to “Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606” [Leuk. Res. 31 (2007) 979–987]
Retraction notice to “Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606” [Leuk. Res. 31 (2007) 979–987]. // Leukemia Research. – URL: https://www.sciencedirect.com/science/article/pii/S0145212626001566?dgcid=rss_sd_all
Retraction notice to “Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606” [Leuk. Res. 31 (2007) 979–987]. Leukemia Research. https://www.sciencedirect.com/science/article/pii/S0145212626001566?dgcid=rss_sd_all
“Retraction notice to “Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606” [Leuk. Res. 31 (2007) 979–987].” Leukemia Research.
@article{article57592,
title = {Retraction notice to “Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606” [Leuk. Res. 31 (2007) 979–987]},
journal = {Leukemia Research},
url = {https://www.sciencedirect.com/science/article/pii/S0145212626001566?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment